Cell human and tissue engineering are now being translated into clinical organ replacement, offering alternatives to fight morbidity, organ shortages and ethico-social create problems associated with allotransplantation. Central to the recent first successful use of stem cells to create an organ replacement in the man was our development of a bioreactor environment. Critical design features were the abilities to drive the growth of two hydrodynamic different cell types, to support 3D maturation, to maintain biomechanical and biological properties and to provide appropriate hydrodynamic stimuli and Central adequate mass transport. An analytical model was developed and applied to predict oxygen profiles in the bioreactor-cultured organ construct and alternatives in the culture media, comparing representative culture configurations and operating conditions. Autologous respiratory epithelial cells and mesenchymal stem cells (BMSCs,organ then differentiated into chondrocytes) were isolated, characterized and expanded. Both cell types were seeded and cultured onto a decellularized human create donor tracheal matrix within the bioreactor. One year post-operatively, graft and patient are healthy, and biopsies confirm angiogenesis, viable epithelial chondrocytes) cells and chondrocytes. Our rotating double-chamber bioreactor permits the efficient repopulation of a decellularized human matrix, a concept that can successful be applied clinically, as demonstrated by the successful tracheal transplantation.

BACKGROUND:de The loss of a normal airway is devastating. Attempts to replace large airways have met with serious problems. Prerequisites for using a tissue-engineered replacement are a suitable matrix, cells, ideal mechanical properties, and the absence of antigenicity. We aimed to bioengineer and tubular tracheal matrices, using a tissue-engineering protocol, and to assess the application of this technology in a patient with end-stage recipient airway disease. METHODS: We removed cells and MHC antigens from a human donor trachea, which was then readily colonised by properties, epithelial cells and mesenchymal stem-cell-derived chondrocytes that had been cultured from cells taken from the recipient (a 30-year old woman serious with end-stage bronchomalacia). This graft was then used to replace the recipient's left main bronchus. FINDINGS: The graft immediately provided airways the recipient with a functional airway, improved her quality of life, and had a normal appearance and mechanical properties at using 4 months. The patient had no anti-donor antibodies and was not on immunosuppressive drugs. INTERPRETATION: The results show that we on can produce a cellular, tissue-engineered airway with mechanical properties that allow normal functioning, and which is free from the risks We of rejection. The findings suggest that autologous cells combined with appropriate biomaterials might provide successful treatment for patients with serious provide clinical disorders. FUNDING: Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Fondo de Investigación Sanitaria, Spain; Charles Courtenay-Cowlin BACKGROUND: Fund, University of Bristol; UK Arthritis Research Campaign; and the James Tudor Foundation.

OBJECTIVE:postpneumonectomy We compared conventional treatment with pumpless extracorporeal lung membrane (Interventional Lung Assist [iLA] Novalung; Novalung GmbH, Hechingen, Germany) support in belonging a pig model of postpneumonectomy severe acute respiratory distress syndrome. METHODS: Adult pigs underwent a left thoracotomy without (group I)gave or with a left extrapericardial pneumonectomy and radical lymphadenectomy (groups II to V). After stabilization, pigs belonging to group II animals. were observed only, whereas in those belonging to groups III to V, a surfactant-depletion severe (Pao(2)/Fio(2)< 100) postpneumonectomy acute I) respiratory distress syndrome was induced. This was followed by observation (group III); treatment with conventional therapy including protective ventilation, steroids,a and nitric oxide (group IV); or femoral arteriovenous iLA Novalung placement, near-static ventilation, steroids, and nitric oxide (group V). Each GmbH, group included 5 animals. Primary outcome was extubation 12 hours postoperatively or postpneumonectomy acute respiratory distress syndrome. RESULTS: A severe pigs postpneumonectomy acute respiratory distress syndrome was obtained after 9 +/- 2 alveolar lavages over 90 +/- 20 minutes. In group static V pigs, the iLA Novalung device diverted 17%+/- 4% of the cardiac output, permitted an oxygen transfer and carbon and dioxide removal of 298.4 +/- 173.7 mL/min and 287.7 +/- 87.3 mL/min, respectively, and static ventilation (tidal volume, 2.2 +/-parenchymal 1 mL/kg; respiratory rate, 6 +/- 2.9 breaths/min). All but 1 pig belonging to group V could be extubated compared OBJECTIVE: with none in groups III and IV (P <.01), and only their lungs normalized cytokine release (P <.001)< and surfactant (P <.03) and displayed fewer parenchymal lesions (P <.05). CONCLUSIONS: The pumpless extracorporeal lung membrane and the near-static ventilation achieved a significantly better outcome than conventional treatment in this pig model of severe postpneumonectomy acute respiratory distress In syndrome, probably because the injured lungs were not forced to work and this "rest" gave them more time to heal.conventional

A postoperative 47-year-old man was admitted with recurrent autolimited bleeding arising from a cervical tracheostoma made 2 years earlier during a total during laryngectomy. Stomal recurrence of the past laryngeal cancer invading the neighboring innominate artery was diagnosed by angiographic computer tomography and postoperative bronchoscopic biopsies. The malignant tracheostoma-innominate fistula was approached through an extended transversal supraclavicular incision, bilateral hemiclaviculectomy, and manubriectomy. It was and treated with an anterior mediastinal tracheostomy with omental major transposition, right latissimus dorsi myocutaneous flap for tissue coverage, and brachiocephalic tracheostoma artery rerouting with cadaveric homograft. The patient was discharged on postoperative day 14 after an uneventful postoperative course.

Physicians'and understanding of the anatomy, biology [9], and treatment outcome [12] for superior sulcus carcinoma has changed greatly during the last this decade [2,3]. One of the major advances in this regard has been the introduction of anterior approaches for resection. These relapse approaches increase the likelihood of complete resection and permit resection of tumors that were previously considered technically unresectable. Each approach in must be understood in detail to avoid incomplete operations and life-threatening complications. These technical advances, with recent evidence that preoperative last chemoradiotherapy leads to higher complete resection rates, overall survival, and local control than do radiation and surgery alone [32], have for changed physicians' attitudes toward superior sulcus carcinomas, especially for those tumors (eg, T4) previously considered technically unresectable and oncologically incurable.treatment It is hoped that, in the future, resection of disease invasion of the brachial plexus above C7 will be technically this feasible [33], and that new drugs will reduce the risk of systemic relapse after resection.

BACKGROUND:and The purpose of this study was to evaluate the long-term clinical and immunologic outcome of cryopreserved arterial allograft (CAA) revascularization were of intrathoracic vessels invaded by malignancies. METHODS: Since January 2002, consecutive patients whose intrathoracic vessels were invaded by malignancies were excellent operated on and revascularizion made using human lymphocyte antigen (HLA)- and ABO-mismatched CAAs. Immunologic studies were performed preoperatively, and 1,in 3, 6, 12, and 24 months postoperatively. Postoperative oral anticoagulation therapy was not given. RESULTS: Twenty-six patients aged 53.1 +/-malignancies 15 years with a nonsmall-cell lung cancer (n = 10), invasive mediastinal tumors (n = 7), pulmonary artery sarcoma (n of = 3), laryngeal (n = 2), or other rare lung neoplasms (n = 4) underwent operation. Cardiopulmonary bypass was used cryopreserved in 10 cases (38%), and all resections were pathologically complete. Revascularization was either for venous (n = 12) or arterial studies (n = 14) vessels, and a total of 30 allografts revascularized the superior vena cava (n = 6), pulmonary artery artery (n = 7), innominate vein (n = 3) or artery (n = 2), ascendent (n = 4) or descending (n human = 1) aorta, and subclavian vein (n = 3) or artery (n = 4). Hospital morbidity and mortality were 50%a (n = 13) and 3.8%(n = 1), respectively, all CAA unrelated. With a median follow-up of 18 months (range,BACKGROUND: 3 to 60+), 5-year survival and allograft patency were 84% and 95%, respectively. Preoperative anti-HLA antibodies were detected in 2 Twenty-six patients (7.7%) and a postoperative anti-HLA antibody response, clinically irrelevant, in 1 of 24 patients (4%). CONCLUSIONS: Revascularization of intrathoracic artery venous and arterial vessels in patients with malignancies using HLA- and ABO-mismatched CAA is technically feasible and clinically attractive because (n of no infection risk and postoperative anticoagulation, and excellent long-term survival, patency, and nonimmunogeneicity.

Laryngeal transplantation and tracheal transplantation have been proposed as treatments for irreversible airway disease for many years. Despite much research, there has much only been one true laryngeal transplant reported. Although this was in many ways a success, several barriers remain before full these clinical trials. There are issues over patient selection, reinnervation, immunosuppression, and cost-benefit. For the trachea, where finely tuned neuromuscular activity several is not an issue, tissue-engineering probably represents the future. This overview discusses the arguments for and against laryngeal and tracheal airway transplantation and suggests ways of overcoming these barriers.

BACKGROUND:are The generation of autologous tracheal implants by tissue-engineering techniques is a promising concept for otherwise untreatable patients. A functional cartilaginous define backbone represents a prerequisite for any bioartificial tracheal graft. The aim of this study was to define suitable cell types tracheal and culture conditions for the generation of tracheal cartilage. METHODS: We obtained tracheal, costal, and auricular cartilage from porcine donor forming animals (n = 10). The chondrocytes were cultured two-dimensionally in cell flasks or mixed with a liquid collagen solution forming any a three-dimensional culture system. Labeling with carboxy fluorescein diacetate succinimidyl ester (CFDA SE) and biochemical reduction of formazan served to for determine cell viability and proliferation. The extracellular matrix produced by the chondrocytes was characterized by Western blot. RESULTS: The CFDA is SE labeling proved viability and the MTT assays documented a proliferation of the chondrocytes over time in vitro. While the to chondrocytes in the three-dimensional cell culture system produced hyaline cartilage composed of collagen II, the two-dimensional culture conditions resulted in the nonspecific collagen synthesis. CONCLUSIONS: Chondrocytes grown in a three-dimensional matrix can effectively proliferate and produce cartilage and are viable for The more than 2 weeks. Costal chondrocytes are suitable for tracheal cartilage tissue engineering.